Do you know how to demonstrate clinical effectiveness to achieve reimbursement success? NAMSA can help you demonstrate evidence of cost to payers to ensure coverage. 

Health Economics Analysis has become increasingly important as payers often demand evidence of cost, not just clinical effectiveness before covering new technology and services. NAMSA works with medtech companies with varying types of analyses which may be required to demonstrate cost effectiveness and to accelerate favorable medical policy coverage.

Cost Analysis provides a complete accounting of the expenses related to a given policy or program decision. It supplies the most basic cost information that both decision makers and practitioners require and forms the foundation of all other economic analyses.

Fiscal Impact Analysis is a comprehensive study of all governmental revenues, expenditures, and savings that will result from the proposed policy or program. This type of analysis helps policymakers determine whether a proposed initiative is affordable from a budgetary standpoint.

Cost Effectiveness Analysis (CEA) is used to evaluate which program or policy creates the result payers want at the lowest cost, and is a valuable tool for weighing programs or policies with similar outcomes.

Cost-Benefit Analysis (CBA) is a method for comparing the economic pros and cons of policies and programs to help policymakers identify the best or most valuable options to pursue. A characteristic feature of CBA is that it monetizes all the benefits and all the costs associated with an initiative so that they can be directly compared.